Stockreport

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

Imunon, Inc.  (IMNN) 
PDF Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented  Initiation of Phase 3 trial sites underway [Read more]